RE:RE:RE:RE:FDASk, that is a big assumtion that the shareprice does not go > $1.00 after a series of carefully calculated strategic announcements. Not sure where you get 40 - 1 as NASDAQ minimum requirements are $1.00 per share are they not?
Revenue will increase quarterly as with any prudently run company.
Any announcement made by the corporation linking Medipharm as the supplier for a generic substitute for Epidolex, and $1.00 shares will be in the rear view mirror forever.
The folks sitting on 50 million shares purchased in the last $30 million private placement who also hold more than 50 milion warrants would not be very happy with a reverse split of any kind